Intraperitoneal cancer therapy

200 Pages·2007·2.264 MB·English

by  C William Helm, Robert P Edwards, M.D

I C T
NTRAPERITONEAL ANCER HERAPY
HHIICCPPRR..iinndddd ii 55//99//22000077 1111::0055::0000 AAMM
C C O
URRENT LINICAL NCOLOGY
Maurie Markman, md, Series Editor
Intraperitoneal Cancer Therapy: edited by C. WILLIAM HELM AND ROBERT P.
EDWARDS, 2007
Colorectal Cancer: Evidence-Based Chemotherapy Strategies, edited by
LEONARD B. SALTZ, 2007
High-Grade Gliomas: Diagnosis and Treatment, edited by GENE H. BARNETT,
2006
Cancer in the Spine: Comprehensive Care, edited by ROBERT F. MCLAIN,
KAI-UWE LEWANDROWSKI, MAURIE MARKMAN, RONALD M. BUKOWSKI,
ROGER MACKLIS, AND EDWARD C. BENZEL, 2006
Squamous Cell Head and Neck Cancer: edited by DAVID J. ADELSTEIN, 2005
Hepatocellular Cancer: Diagnosis and Treatment, edited by BRIAN I. CARR,
2005
Biology and Management of Multiple Myeloma: edited by
JAMES R. BERENSON, 2004
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity
and What Can Be Done, edited by JAMES H. FINKE AND
RONALD M. BUKOWSKI, 2004
Treatment of Acute Leukemias: New Directions for Clinical Research,
edited by CHING-HON PUI, 2003
Allogeneic Stem Cell Transplantation: Clinical Research and Practice,
edited by MARY J. LAUGHLIN AND HILLARD M. LAZARUN, 2003
Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and
Clinical Management, edited by GARY J. SCHILLER, 2003
Colorectal Cancer: Multimodality Management, edited by LEONARD SALTZ,2002
Breast Cancer: A Guide to Detection and Multidisciplinary Therapy, edited
by MICHAEL H. TOROSIAN, 2002
Melanoma: Biologically Targeted Therapeutics, edited by ERNEST C. BORDEN,
2002
Cancer of the Lung: From Molecular Biology to Treatment Guidelines,
edited by ALAN B. WEITBERG, 2001
Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical
Management,edited by RONALD M. BUKOWSKIAND ANDREW NOVICK,2000
Current Controversies in Bone Marrow Transplantation: edited by
BRIAN J. BOLWELL, 2000
Regional Chemotherapy: Clinical Research and Practice, edtied by
MAURIE MARKMAN, 2000
HHIICCPPRR..iinndddd iiii 55//99//22000077 1111::0055::0011 AAMM
I
NTRAPERITONEAL
C T
ANCER HERAPY
Edited by
C W H
. ILLIAM ELM,
MA, MB BChir, FRCS
Department of Obstetrics, Gynecology, and Women’s
Health, Division of Gynecologic Oncology, James Graham
Brown Cancer Center, University of Louisville School of
Medicine, Louisville, KY
and
R P. E
OBERT DWARDS, MD
Vice Chairman of Clinical Affairs, Director, Ovarian
Cancer Center of Excellence, Professor of Obstetrics,
Gynecology, and Reproductive Sciences, University of
Pittsburgh School of Medicine, Pittsburgh, PA
HHIICCPPRR..iinndddd iiiiii 55//99//22000077 44::3399::0033 PPMM
© 2007 Humana Press Inc., a division of Springer Science+Business Media, LLC
999 Riverview Drive, Suite 208
Totowa, New Jersey 07512
humanapress.com
All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in
any form or by any means, electronic, mechanical, photocopying, microfi lming, recording, or otherwise
without written permission from the Publisher.
All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not
necessarily refl ect the views of the publisher.
Due diligence has been taken by the publishers, editors, and authors of this book to assure the accuracy of the information
published and to describe generally accepted practices. The contributors herein have carefully checked to ensure that the
drug selections and dosages set forth in this text are accurate and in accord with the standards accepted at the time of publi-
cation. Notwithstanding, as new research, changes in government regulations, and knowledge from clinical experience
relating to drug therapy and drug reactions constantly occurs, the reader is advised to check the product information provided
by the manufacturer of each drug for any change in dosages or for additional warnings and contraindications. This is of
utmost importance when the recommended drug herein is a new or infrequently used drug. It is the responsibility of the
treating physician to determine dosages and treatment strategies for individual patients. Further it is the responsibility of the
health care provider to ascertain the Food and Drug Administration status of each drug or device used in their clinical practice.
The publisher, editors, and authors are not responsible for errors or omissions or for any consequences from the application
of the information presented in this book and make no warranty, express or implied, with respect to the contents in this
publication.
This publication is printed on acid-free paper. ∞
ANSI Z39.48-1984 (American National Standards Institute) Permanence of Paper for Printed Library
Materials.
Photocopy Authorization Policy:
Authorization to photocopy items for internal or personal use, or the internal or personal use of specifi c
clients, is granted by Humana Press Inc., provided that the base fee of US $30.00 per copy is paid directly
to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations
that have been granted a photocopy license from the CCC, a separate system of payment has been arranged
and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is:
[978-1-58829-878-2/07 $30.00].
10 9 8 7 6 5 4 3 2 1
Library of Congress Control Number: 2006939955
ISBN: 978-1-58829-878-2
e-ISBN: 978-1-59745-195-6
HHIICCPPRR..iinndddd iivv 55//99//22000077 1111::0055::0011 AAMM
Preface
This collaborative work is the result of a gathering of some of the leaders in
the fi eld of intraperitoneal chemotherapy for ovarian cancer and hyperthermic
intraperitoneal chemotherapy for peritoneal carcinomatosis at an International
Symposium held at the University of Louisville, Kentucky, in May 2005. All
the speakers at that symposium have contributed
chapters to this work.
The Symposium was held 25 years after Dr. John
Spratt, a surgeon at the University of Louisville,
reported for the fi rst time ever delivery of hyperther-
mic intraperitoneal chemotherapy to a male patient
with pseudomyxoma peritonei. It is to him that this
book is dedicated.
Although much has happened in the intervening
quarter century, the revolution has been slow to
develop and it is only recently that the tide has
turned widely in favor of directing tumoricidal
therapy to the peritoneal cavity for the treatment of
Dr John Spratt intraperitoneal malignancies. Oncologists of surgi-
1929–2005 cal, gynecologic and medical bents from all over the
World have played their part in these developments.
Professor of Surgery
We hope that this volume will contribute to a greater
University of Louisville understanding of where we are now, how we got
Louisville, KY here, and where we are going.
C. William Helm
Robert P. Edwards
v
HHIICCPPRR..iinndddd vv 55//99//22000077 1111::0055::0011 AAMM
Acknowledgments
The editors extend their thanks to their editorial assistant, Ms. Leta Weedman,
for her guidance and tireless help during the production of this book. We are
also indebted to all the contributors who have so eagerly given their energy and
time to share their knowledge and experience in this exciting new arena of
cancer treatments that will give hope to patients around the world.
vii
HHIICCPPRR..iinndddd vviiii 55//99//22000077 1111::0055::0011 AAMM
Contents
Preface ...................................................................................................................v
Acknowledgments ...............................................................................................vii
Contributors ..........................................................................................................xi
Introduction by David S. Alberts ....................................................................xiii
1. Management of Ovarian Cancer: The Theory ...............................................1
Maurie Markman
2. Management of Ovarian Cancer: Clinical Trials .........................................11
Maurie Markman
3. A Systematic Review and Meta-Analysis of Randomized Trials ...............31
Kenneth Jaaback
4. Immunobiology and Intraperitoneal Immunobiologics in
Ovarian Cancer ........................................................................................45
Ralph S. Freedman
5. Intraperitoneal Chemotherapy: Technique and Complications ...................55
Joan L. Walker
6. Hyperthermia and Chemotherapy: The Science ..........................................71
Roger A. Vertrees, Jeffrey M. Jordan, and
Joseph B. Zwischenberger
7. Hyperthermic Intraperitoneal Chemotherapy in Nongynecologic
Cancers ...................................................................................................101
Bing Yi, Jason M. Foster, and Brian W. Loggie
8. Peritoneal Carcinomatosis of Colorectal Origin ........................................119
Frans A.N. Zoetmulder
9. Cytoreductive Surgery and Hyperthermic Intraperitoneal
Chemotherapy for Ovarian Cancer: Experience in France ...................131
Olivier Glehen and Francois-Noel Gilly
10. Cytoreductive Surgery and Hyperthermic Intraperitoneal
Chemotherapy for Ovarian Cancer: World Experience ........................147
C. William Helm
11. Techniques of Delivering Hyperthermic Intraperitoneal
Chemotherapy ........................................................................................163
Jesus Esquivel, Paul H. Sugarbaker, and C. William Helm
ix
HHIICCPPRR..iinndddd iixx 55//99//22000077 1111::0055::0011 AAMM
x Contents
12. Future Directions in the Delivery of Hyperthermic Intraperitoneal
Chemotherapy ........................................................................................179
Scott Richard and Robert P. Edwards
Index ..................................................................................................................187
HHIICCPPRR..iinndddd xx 55//99//22000077 1111::0055::0011 AAMM
Contributors
David S. Alberts, md • Professor, Director, Arizona Cancer Center
Regents Professor of Medicine, Pharmacology, Nutritional Sciences,
Public Health, and BIO5,University of Arizona, Tucson, AZ
Robert P. Edwards, md • Vice Chairman of Clinical Affairs, Director,
Ovarian Cancer Center of Excellence, Professor of Obstetrics,
Gynecology, and Reproductive Sciences, University of Pittsburgh School
of Medicine, Pittsburgh, PA
Jesus Esquivel, md, facs • Director Peritoneal Surface Malignancy
Program, St. Agnes Hospital, Baltimore, MD
Ralph S. Freedman, md, phd • Professor, University of Texas M D
Anderson Cancer Center, Houston, TX
Jason M. Foster, md • Assistant Professor of Surgical Oncology,
Department of Surgery, Creighton University Medical Center,
Creighton University, Omaha, NE
Francois-Noël Gilly, md, phd • Professor of Surgery, Department of
Oncological Surgery, Centre Hospitalier Lyon Sud, 69495 Lyon, France
Olivier Glehen, md, phd • Professor of Surgery, Department of
Oncological Surgery, Centre Hospitalier Lyon Sud, 69495 Lyon, France
C. William Helm, ma, mb bchir, frcs • Department of Obstetrics,
Gynecology, and Women’s Health, Division of Gynecologic Oncology,
James Graham Brown Cancer Center, University of Louisville School of
Medicine, Louisville, KY
Kenneth Jaaback, mb bch, franzcog • Consultant in Gynecologic
Oncology Bath Royal United Hospital, NHS Trust, Bath, UK
Jeffrey M. Jordan, md, phd candidate • James W. McLaughlin Fellow,
University of Texas Medical Branch, Houston, TX
Brian W. Loggie, md • Professor of Surgery, Director, Cancer Center,
Creighton University Medical Center, Creighton University, Omaha, NE
Maurie Markman, md • Professor, Vice President for Clinical Research,
University of Texas M D Anderson Cancer Center, Houston, TX
Scott Richard, md • Professor of Obstetrics, Gynecology and Reproductive
Sciences, University of Pittsburgh School of Medicine, Pittsburg, PA
PaulH. Sugarbaker,md,facs,frcs • Washington Cancer Institute,
Washington, DC
xi
HHIICCPPRR..iinndddd xxii 55//99//22000077 1111::0055::0011 AAMM